Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study

BackgroundThe ORAL Surveillance trial showed a potentially higher incidence of malignancy and major adverse cardiovascular events (MACEs) associated with tofacitinib than those associated with tumor necrosis factor (TNF) inhibitors (TNFis). However, few studies have compared the safety of non-TNFis...

Full description

Bibliographic Details
Main Authors: Shuhei Yoshida, Masayuki Miyata, Eiji Suzuki, Takashi Kanno, Yuya Sumichika, Kenji Saito, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Kiyoshi Migita
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
rheumatoid arthritis
tofacitinib
baricitinib
JAK inhibitor
IL-6 inhibitor
malignancy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267749/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267749/full

Similar Items